Corrigendum to: The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg 1545 cleavage site (Journal of Thrombosis and Haemostasis, (2017), 15, 1, (140-149), 10.1111/jth.13559);The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 1, 2017, Pages 140-149

  van Doorn, P ^a   Rosing, J ^a   Wielders, S J ^a   Hackeng, T M ^a   Castoldi, E ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

factor V; factor Xa; prothrombinase complex; thrombin; tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; ARGININE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; PEPTIDE; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR ALPHA; UNCLASSIFIED DRUG; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PROTEIN BINDING;

ADULT; AMINO ACID SEQUENCE; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN INTERACTION; BINDING SITE; CHEMISTRY; PROTEIN DOMAIN;

ADULT; ANTICOAGULANTS; ARGININE; BINDING SITES; FACTOR V; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LIPOPROTEINS; MALE; PEPTIDES; PROTEIN BINDING; PROTEIN DOMAINS; THROMBIN;

EID: 85006096915     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14489     Document Type: Erratum

References (29)

1. Dahlbäck B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol 2016; 38: 4–11.
2. Zhu H, Toso R, Camire RM. Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state. J Biol Chem 2007; 282: 15033–9.
3. Bos MHA, Camire RM. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem 2012; 287: 26342–51.
4. Bunce MW, Bos MH, Krishnaswamy S, Camire RM. Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides. J Biol Chem 2013; 288: 30151–60.
5. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990; 29: 1118–28.
6. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem 1997; 247: 12–20.
7. Keller FG, Ortel TL, Quinn-Allen M-A, Kane WH. Thrombin-catalyzed activation of recombinant human factor V. Biochemistry 1995; 34: 4118–24.
8. Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556–64.
9. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274–83.
10. Steen M, Dahlbäck B. Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site. J Biol Chem 2002; 277: 38424–30.
11. Duckers C, Simioni P, Spiezia L, Radu C, Gavasso S, Rosing J, Castoldi E. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112: 3615–23.
12. Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934–43.
13. Ndonwi M, Girard TJ, Broze GJ Jr. The C-terminus of tissue factor pathway inhibitor alpha is required for its interaction with factors V and Va. J Thromb Haemost 2012; 10: 1944–6.
14. Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA 2013; 110: 17838–43.
15. Peraramelli S, Thomassen S, Heinzmann A, Hackeng TM, Hartmann R, Scheiflinger F, Dockal M, Rosing J. Role of exosite binding modulators in the inhibition of fxa by TFPI. Thromb Haemost 2016; 115: 580–90.
16. Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 2013; 123: 3777–87.
17. Peraramelli S, Suylen DP, Rosing J, Hackeng TM. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Thromb Haemost 2012; 108: 266–76.
18. Omarova F, Uitte De Willige S, Ariens RA, Rosing J, Bertina RM, Castoldi E. Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen gamma’. J Thromb Haemost 2013; 11: 1669–78.
19. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249–53.
20. Hackeng TM, Suylen DPL, Hemker HC, Apitz-Castro RJ. Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces. Google Patents 2013, WO 2013028069A1.
21. Marquette KA, Pittman DD, Kaufman RJ. The factor V B-domain provides two functions to facilitate thrombin cleavage and release of the light chain. Blood 1995; 86: 3026–34.
22. Broze GJ Jr, Girard TJ. Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder. J Clin Invest 2013; 123: 3710–12.
23. Camire RM. Rethinking events in the haemostatic process: role of factor V and TFPI. Haemophilia 2016; 22(Suppl. 5): 3–8.
24. Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009; 29: 2015–20.
25. Toso R, Bunce MW, Camire RM. The C-terminus basic region of TFPIα dynamically regulates FV(a) function: evaluation of FV-short. Blood 2014; 124: 578 (abstract).
26. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735–8.
27. Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140–5.
28. Castoldi E, Rosing J. Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 2004; 11: 176–81.
29. Váradi K, Moritz B, Lang H, Bauer K, Preston E, Peake I, Rivard GE, Keil B, Schwarz HP. A chromogenic assay for activated protein C resistance. Br J Haematol 1995; 90: 884–91.